Feb. 1 at 10:15 PM
$ALT Jeffries reiterated $ 28 PT is a conservative, risk-adjusted figure imo (i.e. recognition that drug candidate is still in clinical trial development).
Assuming a successful P3 & NDA, the re-rate would be much closer to MDGL territory imo.
BP's who could benefit in my view:
$SNY - instantly establishes one of the top global GCGR (and GLP-1) drug pipelines in Pharma with Pemvi
$GILD - establishes dominance across the Liver steatosis spectrum (i.e. complements world-class PBC and Hepatitis franchises)
$MDGL - establishes a world-class next-gen MOA Liver drug portfolio (THR-B, GCGR)
$PFE - potential to transform Pemvi into the equivalent of the cardiometabolic disease age Lipitor 2.0
Disclosure: Long Altimmune (Pemvi GCGR) and Sanofi, not medical / investment advice.
